High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP.
Patients and Methods
Patients ≥18 years of age who were hospitalized with moderate to severe COVID-19 infection and received CCP at the MD Anderson Cancer Center between 4/30/2020 and 8/20/2020 were included in the study. We quantified the levels of anti-SARS-CoV-2 antibodies, as well as antibodies against antigens of other coronavirus strains, in the CCP units and compared antibody levels with patient outcomes. For each antibody, a Bayesian exponential survival time regression model including prognostic variables was fit, and the posterior probability of a beneficial effect (PBE) of higher antibody level on survival time was computed.
Results
CCP was administered to 44 cancer patients. The median age was 60 years (range 37-84) and 19 (43%) were female. Twelve patients (27%) died of COVID-19-related complications. Higher levels of two non-SARS-CoV-2-specific antibodies, anti-HCoV-OC43 spike IgG and anti-HCoV-HKU1 spike IgG, had PBE = 1.00, and 4 SARS-CoV-2-specific antibodies had PBEs between 0.90 and 0.95. Other factors associated with better survival were shorter time to CCP administration, younger age, and female sex.
Conclusions
Common cold coronavirus spike IgG antibodies anti-HCoV-OC43 and anti-HCoV-HKU1 may target a common domain for SARS-CoV-2 and other coronaviruses. They provide a promising therapeutic target for monoclonal antibody production.
Article activity feed
-
-
SciScore for 10.1101/2021.03.08.21252775: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources The 10 anti-SARS-CoV-2 antibodies were measured in each of the CCP products that were administered to all 44 patients in our study, while the 8 additional antibodies against other coronavirus strains were measured in the CCP products of 25 of those patients. anti-SARS-CoV-2suggested: NoneThis discrepancy in sampling was because the 8 other anti-coronavirus-associated protein antibody tests had not been developed at the time the study commenced. anti-coronavirus-associated proteinsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources In each model, it was assumed that log (mean survival … SciScore for 10.1101/2021.03.08.21252775: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources The 10 anti-SARS-CoV-2 antibodies were measured in each of the CCP products that were administered to all 44 patients in our study, while the 8 additional antibodies against other coronavirus strains were measured in the CCP products of 25 of those patients. anti-SARS-CoV-2suggested: NoneThis discrepancy in sampling was because the 8 other anti-coronavirus-associated protein antibody tests had not been developed at the time the study commenced. anti-coronavirus-associated proteinsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources In each model, it was assumed that log (mean survival time) = b0 + b1 age + b2[Female] + b3[time to infusion ≤ 3 days] + b4Z, with the parameter b4 quantifying the additional effect of the antibody level on survival time. b0 + b1 age + b2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04338360 Approved for marketing Expanded Access to Convalescent Plasma for the Treatment of … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
